SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced that management will participate in two upcoming investor conferences.
2024 UBS Global Healthcare Conference
Format: Fireside chat with analyst, Trung Huynh, and 1x1 meetings
Date: Tuesday, November 12
Time: 3:30 PM PST
Location: Rancho Palos Verdes, CA
Webcast link: Available here
2024 Jefferies London Healthcare Conference
Format: Fireside chat with analyst, Michael Yee, and 1x1 meetings
Date: Tuesday, November 19
Time: 9:00 AM GMT
Location: London, UK
Webcast link: Available here
The live webcasts for the UBS and Jefferies fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
| Last Trade: | US$1.85 |
| Daily Change: | -0.01 -0.54 |
| Daily Volume: | 1,138,187 |
| Market Cap: | US$97.570M |
December 12, 2024 December 10, 2024 November 07, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
